U.S. Markets closed

United Health Products, Inc. (UEEC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.2000+0.0400 (+3.45%)
At close: 12:56PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1600
Open1.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.1722 - 1.2200
52 Week Range0.5100 - 1.9000
Volume22,445
Avg. Volume181,165
Market Cap225.928M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-0.0730
Earnings DateJun 29, 2020 - Jun 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    United Health Products Announces Leadership Changes

    United Health Products, Inc. (OTC: UEEC), ("UHP" or the "company"), developer, manufacturer and marketer of HemoStyp®, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced changes to its senior management team and its Board of Directors.

  • Business Wire

    United Health Products Announces Journal of Wound Care to Publish HemoStyp® Human Trial Peer Reviewed Article

    United Health Products, Inc. (OTC: UEEC) ("UHP" or the "Company"), developer, manufacturer and marketer of HemoStyp, a patented Oxidized Regenerated Cellulose (ORC), today announced that the Journal of Wound Care, headquartered in London, England, has informed the Company that UHP’s submitted article, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, has been accepted for publication in the November 2020 edition. This article, which was peer reviewed, was authored by Raymond Schaerf, MD, Sasan Najibi, MD, John Conrad, MD, and Gerard Abate, MD. This journal submission highlights the results of the study showing HemoStyp’s superiority to Surgicel®, an Ethicon Inc. product, a division of Johnson & Johnson.

  • Business Wire

    United Health Products Submits HemoStyp® Completed PMA Response to FDA

    United Health Products, Inc. (OTCPK: UEEC, "UHP") today announced that it has submitted documents requested by the FDA in conjunction with its PMA (Class III) application to use HemoStyp in internal surgeries. The company expects the FDA to grant approval to its PMA (Class III) application or request additional information within 30 days.